Jefferies Group LLC Biocryst Pharmaceuticals Inc Transaction History

Jefferies Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 21, 2023	BUY	$7.89 - $17.88 $549,696 - $1.25 Million	69,670 Added 1083.51%	76,100 $805,000
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $600,429 - $1.36 Million	76,100 New	76,100 $805,000
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $61,085 - $110,853	-6,430 Closed	0 $0
Q1 2021 Sep 21, 2023	BUY	$7.37 - $13.61 $47,389 - $87,512	6,430 New	6,430 $65,000
Q1 2021 May 14, 2021	SELL	$7.37 - $13.61 $91,380 - $168,750	-12,399 Reduced 65.85%	6,430 $65,000
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $473,873 - $1.22 Million	-296,171 Reduced 94.02%	18,829 $38,000
Q4 2019 Feb 13, 2020	BUY	$1.59 - $3.45 $500,850 - $1.09 Million	315,000 New	315,000 $1.09 Million

260

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.43B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.